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Background
Merozoite surface protein 3, a leading malaria vaccine
candidate, is expressed in schizont stage as 48 kDa non
GPI anchored protein which remains associated with
merozoite surface after egress. Role of MSP3 in parasite
growth is not well defined.-MSP3 is abundantly
expressed on the surface of merozoites and is released as
a soluble protein. Recently suggested nomenclature has
placed MSP3 in a new MSP3 multigene family and
termed it MSP3.1. MSP3.1 has been shown to be the
least cross-reactive among the members of the MSP3
family. Affinity-purified MSP3 antibodies from the sera
of P. falciparum-exposed individuals and antibodies from
mice vaccinated with MSP3 peptides exhibited ADCI
activity (15, 21). Aotus monkeys vaccinated with yeast
(Pichia pastoris) expressed full-length MSP3 (MSP3F)
were partially protected from a challenge with P. falci-
parum parasites. Antigenicity and functional assays have
identified a 70-amino-acid conserved domain in the N-
terminal region of MSP3 to be a target of biologically
active antibodies. Long synthetic peptides based on the
conserved N-terminal sequences, including the 70-
amino-acid sequence, have been developed for vaccine
trials in humans.
Materials and methods
Recombinant Plasmodium falciparum merozoite surface
protein 3 (PfMSP3F) and a 24-kDa fragment from its N
terminus (MSP3N) that includes the essential conserved
domain, which elicits the maximum antibody (Ab)-
dependent cellular inhibition (ADCI), were expressed as
soluble proteins in Escherichia coli. Both proteins were
found to be stable in both soluble and lyophilized forms.
Immunization with MSP3F and MSP3N formulated sepa-
rately with two human-compatible adjuvants, aluminum
hydroxide (Alhydrogel) and Montanide ISA 720, pro-
duced significant antibody responses in mice and rabbits.
Polyclonal Abs against both antigens recognized native
MSP3 in the parasite lysate. These two Abs also recog-
nized two synthetic peptides, previously characterized to
possess B cell epitopes from the N-terminal region. Anti-
body depletion assay showed that most of the IgG
response is directed toward the N-terminal region of the
full protein. Anti-MSP3F and anti-MSP3N rabbit antibo-
dies did not inhibit merozoite invasion or intraerythrocy-
tic development but significantly reduced parasitemia in
the presence of human monocytes. The ADCI demon-
strated by anti-MSP3N antibodies was comparable to
that exhibited by anti-MSP3F antibodies (both generated
in rabbit).
Conclusions
Our work in this study has demonstrated that although
immunizations with the full-length MSP3 leads to a sub-
stantial antibody response to the epitopes present in the
N-terminal region, the N-terminal polypeptide fragment
itself elicits a strong and effective immune response that
makes it a strong vaccine candidate.
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